Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.47 |
| ▸ | JAK3 | P52333 | 12/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.46 |
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | CDK9 | P50750 | 5/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.45 |
| ▸ | CDK7 | P50613 | 3/20 | 0.45 |
| ▸ | CCNH | P51946 | 3/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16009804 | 0.86 | JAK2 (0.52) | JAK2JAK3EGFRPTK2CDK2 | |
| SCHEMBL17968674 | 0.82 | JAK2 (0.46) | JAK2JAK3PTK2CDK2CCNA2 | |
| SCHEMBL16009359 | 0.77 | JAK2 (0.49) | JAK2JAK3EGFRPTK2CDK2 | |
| SCHEMBL25209784 | 0.76 | CDK2 (0.57) | JAK2JAK3PTK2CDK2CDK9 | |
| SCHEMBL30347186 | 0.76 | CDK2 (0.57) | JAK2JAK3PTK2CDK2CDK9 | |
| SCHEMBL16010469 | 0.75 | JAK2 (0.41) | JAK2JAK3EGFRPTK2CDK2 | |
| SCHEMBL16009268 | 0.73 | PIK3CD (0.49) | JAK2JAK3PTK2CDK2CDK9 | |
| SCHEMBL7467387 | 0.73 | CDK2 (0.64) | JAK2JAK3EGFRPTK2CDK2 | |
| SCHEMBL25157198 | 0.72 | CDK2 (0.43) | JAK2JAK3PTK2CDK2CDK9 | |
| SCHEMBL477172 | 0.71 | KDM4E (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | JAK2 320/4885JAK3 367/4885EGFR 471/4885 |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | JAK2 320/4885JAK3 367/4885EGFR 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.